ClinicalTrials.gg
CompletedNCT03915964RA-BRIDGEUpdated Jun 24, 2026Results posted

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

A Phase 4 interventional study of Baricitinib and TNF Inhibitor in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 261 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,659
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Enrollment
2nd of 23
2,659 · median 290
Started
2019
the only one that year
Phase 4
9 of 23
3 open now
Registered
14th of 23
by date
Lead sponsor
11 of 23
Eli Lilly and Company

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 9 in phase 4, and was the 14th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have at least one of the following characteristics:

    • Documented evidence of a VTE prior to this study
    • At least 60 years of age
    • A (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²), or
    • Age 50 to less than 60 years and BMI 25 to less than 30 kg/m².
  • Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drug (DMARD) (synthetic or biologic).

Exclusion criteria

Exclusion Criteria:

  • Participant should have no reason to not take a TNF inhibitor.
  • Participants must not be pregnant or breastfeeding.
  • Participants must not have had more than one VTE.
  • Participants must not have cancer.
  • Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness.
  • Participants must not have had a within four weeks of study start.
  • Participants must not have participated in any other clinical trial within four weeks of study start.
  • Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,659 participants (actual)

Study arms

  • Experimental
    Baricitinib 2mg

    Participants received 2 milligrams (mg) of baricitinib once daily until the planned number of adjudicated primary endpoint events occurred or until the data monitoring committee (DMC) recommended early termination. Those with inadequate response at 1-year after start of treatment with baricitinib 2mg could receive rescue treatment with baricitinib 4mg.

    Drug: Baricitinib

  • Experimental
    Baricitinib 4mg

    Participants received 4 mg of baricitinib once daily until the planned number of adjudicated primary endpoint events occurred or until the DMC recommended early termination.

    Drug: Baricitinib

  • Active comparator
    Tumor Necrosis Factor (TNF) Inhibitor

    Participants received a TNF inhibitor (adalimumab or etanercept) administered according to approved local labeling until the planned number of adjudicated primary endpoint events occurred or until the DMC recommended early termination.

    Drug: TNF Inhibitor

Interventions

  • Administered orally.

    Also known as: LY3009104

  • DrugTNF Inhibitor

    Administered subcutaneously.

    Also known as: Etanercept, Adalimumab

06

What researchers measure

Primary outcomes

  1. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

Secondary outcomes

  1. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

  2. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first ATE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

  3. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first MACE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

  4. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Malignancy (Excluding Nonmelanoma Skin Cancer [NMSC]) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first malignancy (excluding NMSC) was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

  5. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Opportunistic Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first opportunistic infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

  6. Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Serious Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

    Time from first dose of study treatment to first serious infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

    Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)

Other outcomes

  1. Total Duration of Treatment Exposure for Combined Baricitinib Dose, Individual Baricitinib Dose and TNF Inhibitor

    Duration of exposure was calculated as: * Baricitinib 2mg exposure = date of last baricitinib 2mg treatment - date of first baricitinib 2mg dose + 1. For participants who were rescued from baricitinib 2 mg to 4 mg, their drug exposure after rescue was censored and not counted as exposure to baricitinib 2mg. * Baricitinib 4mg exposure = date of last baricitinib 4mg treatment - date of first baricitinib 4mg dose + 1. * TNF inhibitor exposure = date of last TNFi (adalimumab or etanercept) - date of first TNFi dose (adalimumab or etanercept) + 1, regardless of treatment cycling from adalimumab to etanercept or vice versa. * Total baricitinib exposure (2/4 mg) = date of last baricitinib (2mg or 4mg) treatment - date of first baricitinib (2mg or 4mg) dose + 1, regardless of rescue from baricitinib 2mg to baricitinib 4mg. Patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen divided by 365.25.

    Time frame: From the date of first dose of study drug up to the last dose (approximately up to 6.1 years)

07

Results

Posted Jun 24, 2026
Limitations and caveats
The treatment was not blinded for the participants, study site personnel, and clinical research associates. This open label design might have introduced some bias, for example in reporting of relatedness of adverse events.

Participant flow

Participant flow — Overall Study
MilestoneBaricitinib 2mgBaricitinib 4mgTumor Necrosis Factor (TNF) Inhibitor
Started886886887
Safety analysis set879881880
Pooled analysis set121912141207
Completed433428415
Not completed453458472
Withdrew: Adverse event112120110
Withdrew: Death163223
Withdrew: Protocol deviation101615
Withdrew: Withdrawal by subject124109130
Withdrew: Physician decision161319
Withdrew: Lack of efficacy553746
Withdrew: Pregnancy023
Withdrew: Russia sites closed due to operational limitations & participants unable to attend their final visit535959
Withdrew: Site terminated by sponsor113
Withdrew: Lost to follow-up403733
Withdrew: Other263231

Outcome measures

PrimaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · Hazard ratio (hr): 1.606 · 95% CI 0.969 to 2.660
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · Hazard ratio (hr): 1.704 · 95% CI 0.943 to 3.079
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · Hazard ratio (hr): 1.688 · 95% CI 0.968 to 2.943
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first ATE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · p = 0.848 · Hazard ratio (hr): 1.102 · 95% CI 0.408 to 2.980
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · p = 0.481 · Hazard ratio (hr): 1.365 · 95% CI 0.574 to 3.243
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · p = 0.737 · Hazard ratio (hr): 1.145 · 95% CI 0.521 to 2.516
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first MACE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · p = 0.911 · Hazard ratio (hr): 1.038 · 95% CI 0.542 to 1.987
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · p = 0.519 · Hazard ratio (hr): 1.204 · 95% CI 0.685 to 2.116
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · p = 0.824 · Hazard ratio (hr): 1.059 · 95% CI 0.638 to 1.760
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Malignancy (Excluding Nonmelanoma Skin Cancer [NMSC]) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first malignancy (excluding NMSC) was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Malignancy (Excluding Nonmelanoma Skin Cancer [NMSC]) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Malignancy (Excluding Nonmelanoma Skin Cancer [NMSC]) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · p = 0.077 · Hazard ratio (hr): 1.526 · 95% CI 0.955 to 2.438
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · p = 0.572 · Hazard ratio (hr): 1.142 · 95% CI 0.721 to 1.810
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · p = 0.239 · Hazard ratio (hr): 1.270 · 95% CI 0.853 to 1.890
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Opportunistic Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first opportunistic infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Opportunistic Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Opportunistic Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · p = 0.998 · Hazard ratio (hr): 0.999 · 95% CI 0.303 to 3.293
  • Baricitinib 4mg vs TNF Inhibitor · Regression, Cox · p = 0.465 · Hazard ratio (hr): 1.470 · 95% CI 0.523 to 4.132
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · p = 0.642 · Hazard ratio (hr): 1.252 · 95% CI 0.485 to 3.228
SecondaryPooled JAJA and JAJD: Time From First Dose of Study Treatment to First Serious Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]

Time from first dose of study treatment to first serious infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.

Time frame:
From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Reported as:
Median · Days
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Serious Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
DaysBaricitinib 2mgBaricitinib 4mgBaricitinib 2/4 mgTNF Inhibitor
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Serious Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Baricitinib 2mg vs TNF Inhibitor · Regression, Cox · p = 0.262 · Hazard ratio (hr): 1.185 · 95% CI 0.881 to 1.593
  • Baricitinib 4mg vs TNF Inhibitor · Cox proportional hazards regression · p = 0.045 · Hazard ratio (hr): 1.320 · 95% CI 1.007 to 1.731
  • Baricitinib 2/4 mg vs TNF Inhibitor · Regression, Cox · p = 0.022 · Hazard ratio (hr): 1.323 · 95% CI 1.040 to 1.681
Other pre-specifiedTotal Duration of Treatment Exposure for Combined Baricitinib Dose, Individual Baricitinib Dose and TNF Inhibitor

Duration of exposure was calculated as: * Baricitinib 2mg exposure = date of last baricitinib 2mg treatment - date of first baricitinib 2mg dose + 1. For participants who were rescued from baricitinib 2 mg to 4 mg, their drug exposure after rescue was censored and not counted as exposure to baricitinib 2mg. * Baricitinib 4mg exposure = date of last baricitinib 4mg treatment - date of first baricitinib 4mg dose + 1. * TNF inhibitor exposure = date of last TNFi (adalimumab or etanercept) - date of first TNFi dose (adalimumab or etanercept) + 1, regardless of treatment cycling from adalimumab to etanercept or vice versa. * Total baricitinib exposure (2/4 mg) = date of last baricitinib (2mg or 4mg) treatment - date of first baricitinib (2mg or 4mg) dose + 1, regardless of rescue from baricitinib 2mg to baricitinib 4mg. Patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen divided by 365.25.

Time frame:
From the date of first dose of study drug up to the last dose (approximately up to 6.1 years)
Reported as:
Number · patient-years
Total Duration of Treatment Exposure for Combined Baricitinib Dose, Individual Baricitinib Dose and TNF Inhibitor
patient-yearsBaricitinib 2mgBaricitinib 4mgTNF InhibitorBaricitinib 2/4 mg
Total Duration of Treatment Exposure for Combined Baricitinib Dose, Individual Baricitinib Dose and TNF Inhibitor2164.33252.73158.16404.8

Adverse events

Collected over From the time of the informed consent signature up to the last study visit (approximately up to 6.1 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baricitinib 2mg16/886 (1.8%)259/879 (29.5%)498/879 (56.7%)
Baricitinib 4mg32/886 (3.6%)276/881 (31.3%)538/881 (61.1%)
TNF Inhibitor23/887 (2.6%)259/880 (29.4%)475/880 (54%)
Most frequent serious events
Showing 10 of 471
Most frequent serious events
EventBaricitinib 2mgBaricitinib 4mgTNF Inhibitor
OsteoarthritisMusculoskeletal and connective tissue disorders18/87923/88111/880
Covid-19 pneumoniaInfections and infestations22/87920/88112/880
Covid-19Infections and infestations15/87918/88110/880
PneumoniaInfections and infestations11/87918/88114/880
Pulmonary embolismRespiratory, thoracic and mediastinal disorders8/87915/8816/880
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1941/1792/178
Benign prostatic hyperplasiaReproductive system and breast disorders1/1942/1790/178
Deep vein thrombosisVascular disorders9/8799/8814/880
Acute myocardial infarctionCardiac disorders4/8799/8813/880
Atrial fibrillationCardiac disorders6/8797/8818/880
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBaricitinib 2mgBaricitinib 4mgTNF Inhibitor
Covid-19Infections and infestations183/879205/881171/880
NasopharyngitisInfections and infestations102/879122/881115/880
Urinary tract infectionInfections and infestations99/879100/88167/880
Upper respiratory tract infectionInfections and infestations86/87992/88177/880
HypertensionVascular disorders71/87988/88174/880
BronchitisInfections and infestations62/87984/88153/880
Herpes zosterInfections and infestations48/87963/88121/880
Rheumatoid arthritisMusculoskeletal and connective tissue disorders55/87955/88162/880
HeadacheNervous system disorders46/87957/88141/880
OsteoarthritisMusculoskeletal and connective tissue disorders37/87952/88142/880

Baseline characteristics

All participants from the safety analysis set.

Age, Continuous
Age, Continuous(years)Baricitinib 2mgBaricitinib 4mgTNF InhibitorTotal
Mean60.10 ± 9.8759.60 ± 9.8660.50 ± 10.2460.10 ± 9.99
Sex: Female, Male
Sex: Female, Male(Participants)Baricitinib 2mgBaricitinib 4mgTNF InhibitorTotal
Female6857027022089
Male194179178551
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baricitinib 2mgBaricitinib 4mgTNF InhibitorTotal
Hispanic or Latino857476235
Not Hispanic or Latino7307287242182
Unknown or Not Reported647980223
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baricitinib 2mgBaricitinib 4mgTNF InhibitorTotal
American Indian or Alaska Native47516
Asian12202658
Native Hawaiian or Other Pacific Islander3003
Black or African American39331789
White8048028132419
More than one race1258
Unknown or Not Reported16171447
Region of Enrollment
Region of Enrollment(Participants)Baricitinib 2mgBaricitinib 4mgTNF InhibitorTotal
Australia2115743
Austria3148
Belgium79420
Czechia121115109345
Denmark1214
France74516
Germany17312674
Greece54817
Hungary344241117
Israel34382597
Italy106824
Lithuania74415
Netherlands45413
Poland151129136416
Romania433935117
Russia677591233
Slovakia13181748
South Africa313240103
Spain526169182
Switzerland77115
Turkey64515
United Kingdom13171646
United States225223224672
08

Study locations

261 sites
  • Arizona Arthritis & Rheumatology Research, PLLC
    Flagstaff, Arizona 86001, United States
  • Arthrocare, Arthritiscare & Research PC
    Gilbert, Arizona 85234, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Glendale, Arizona 85306, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Mesa, Arizona 85210, United States
  • Hope Research Institute
    Peoria, Arizona 85381, United States
  • Hope Research Institute
    Phoenix, Arizona 85018, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Tucson, Arizona 85704, United States
  • Medvin Clinical Research - Covina
    Covina, California 91722, United States
  • St Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • Christine Thai, MD
    Huntington Beach, California 92648, United States
  • Private Practice - Dr. Christine J. Leehealey
    Irvine, California 92604, United States
  • Desert Medical Advances
    Rancho Mirage, California 92270, United States
  • Rheumatology Center of San Diego
    San Diego, California 92128, United States
  • East Bay Rheumatology Medical Group, Inc
    San Leandro, California 94578, United States
  • Dan La, MD Inc
    Tujunga, California 91042, United States
  • Robin K. Dore MD, Inc
    Tustin, California 92780, United States
  • Inland Rheumatology & Osteoporosis Medical Group
    Upland, California 91786, United States
  • Medvin Clinical Research - Weidmann
    Van Nuys, California 91405, United States
  • Medvin Clinical Research - Whittier
    Whittier, California 90602, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Rheumatology Associates of South Florida
    Boca Raton, Florida 33486, United States
  • Suncoast Research Group
    Miami, Florida 33135, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • IRIS Research and Development, LLC
    Plantation, Florida 33324, United States
  • Qps-Mra, Llc
    South Miami, Florida 33143, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Arthritis & Rheumatology of Georgia
    Atlanta, Georgia 30342, United States
  • Arthritis Center of North Georgia
    Gainesville, Georgia 30501, United States
  • St. Luke's Intermountain Research Center
    Boise, Idaho 83702, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Qualmedica Research, LLC
    Evansville, Indiana 47715, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67205, United States
  • Center for Arthritis and Osteoporosis
    Elizabethtown, Kentucky 42701, United States
  • Accurate Clinical Research
    Lake Charles, Louisiana 70605, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • NECCR PrimaCare Research
    Fall River, Massachusetts 02721, United States
  • University of Michigan
    Brighton, Michigan 48116, United States
  • West Michigan Rheumatology
    Grand Rapids, Michigan 49546, United States
  • Advanced Rheumatology, PC
    Okemos, Michigan 48864, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC
    Springfield, Missouri 65807, United States
  • Glacier View Research Institute
    Kalispell, Montana 59901, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Westroads Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • Allied Clinical Research
    Reno, Nevada 89519, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Albuquerque Center for Rheumatology
    Albuquerque, New Mexico 87102, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Santa Fe Rheumatology
    Santa Fe, New Mexico 87505, United States
  • Accellacare - Charlotte
    Charlotte, North Carolina 28211, United States
  • M3-Emerging Medical Research, LLC
    Durham, North Carolina 27704, United States
  • Piedmont Rheumatology, P.A.
    Hickory, North Carolina 28602, United States
  • Cape Fear Arthritis Care
    Leland, North Carolina 28451, United States
  • PMG Research of Salisbury
    Salisbury, North Carolina 28144, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Cincinnati Rheumatic Disease Study Group
    Cincinnati, Ohio 45242, United States
  • Marietta Memorial Hospital
    Marietta, Ohio 45750, United States
  • Paramount Medical Research & Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104, United States
  • East Penn Rheumatology Associates
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Center of Reading,LLC
    Wyomissing, Pennsylvania 19610, United States
  • Pennsylvania Regional Center for Arthritis and Osteoporosis Research
    Wyomissing, Pennsylvania 19610, United States
  • Regional Health Clinical Research
    Rapid City, South Dakota 57701, United States
  • Accurate Clinical Management
    Baytown, Texas 77521, United States
  • Arthritis & Osteoporosis Clinic of Brazos Valley
    College Station, Texas 77845, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • Accurate Clinical Management - Houston
    Houston, Texas 77084, United States
  • Accurate Clinical Research
    Houston, Texas 77089, United States
  • Research Physicians Network, LLC
    Houston, Texas 77089, United States
  • Accurate Clinical Research
    League City, Texas 77573, United States
  • Accurate Clinical Research, Inc.
    San Antonio, Texas 78229, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Accurate Clinical Management
    Sugar Land, Texas 77479, United States
  • Dynamed Clinical Research, LP d/b/a DM Clinical Research
    Tomball, Texas 77375, United States
  • DM Clinical Research/Rheumatology Clinic of Houston
    Tomball, Texas 77377, United States
  • Arthritis Northwest, PLLC
    Spokane, Washington 99204, United States
  • The Vancouver Clinic
    Vancouver, Washington 98664, United States
  • CAMC Health Education and Research Institute Inc
    Charleston, West Virginia 25304, United States
  • Optimus Clinical Research
    Botany, New South Wales 2019, Australia
  • Genesis Research Services
    Newcastle, New South Wales 2292, Australia
  • Rheumatology Research Unit
    Maroochydore, Queensland 4558, Australia
  • Southern Clinical Research
    Hobart, Tasmania 7000, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Medizinische Universität Wien
    Vienna, State of Vienna 1090, Austria
  • Wilhelminenspital
    Vienna, State of Vienna 1160, Austria
  • Rheuma-Zentrum Oberlaa GmbH
    Vienna, 1100, Austria
  • Université Libre de Bruxelles - Hôpital Erasme
    Brussels, Bruxelles-Capitale, Région de 1070, Belgium
  • ZNA Jan Palfijn
    Merksem, Flanders 2170, Belgium
  • Reuma Clinic, Locatie Jaarbeurslaan
    Genk, Limburg 3600, Belgium
  • Revmacentrum MUDr. Mostera, s.r.o.
    Brno, Brno-město 61500, Czechia
  • Revmatologie.s.r.o.
    Brno, Brno-město 63800, Czechia
  • Artroscan, s.r.o.
    Ostrava, Moravian-Silesian Region 722 00, Czechia
  • INREA s.r.o.
    Ostrava, Ostrava Město 70300, Czechia
  • ARTHROHELP s.r.o.
    Pardubice, Pardubice Region 53002, Czechia
  • Clintrial s.r.o.
    Prague, Praha 10 100 00, Czechia
  • Revmatologie MUDr. Štejfová
    Prague, Praha 4 140 00, Czechia
  • Revmatologicky ustav
    Prague, Praha, Hlavní Mešto 12850, Czechia

Showing the first 100 of 261 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in May 2025, 73 months.

Results were first posted in Jun 2026, 1 year after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 73 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2019
First posted
Apr 16, 2019
StartActual
Apr 25, 2019
Primary completionActual
May 28, 2025
CompletionActual
May 28, 2025
Results first posted
Jun 24, 2026
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03915964
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Apr 25, 2019
Primary completion
May 28, 2025
Completion
May 28, 2025
Results posted
Jun 24, 2026
Last update
Jun 24, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion